Answers are grounded in this paper and cite their sources.
During immunosuppression with cyclosporine, gingival overgrowth, a minor secondary effect, may appear in the first weeks of treatment. In certain cases it may affect the function and/or esthetic appearance in a manner intolerable to the patient. A new immunnosuppressive molecule, tacrolimus, presently used as a treatment of second choice to control acute corticoresistant rejection, may bring oral comfort to these patients, since it reduces gingival overgrowth to negligible levels.
No takes yet. Share an insight, caveat, or question.
Bader et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: